11/9/2022 0 Comments Chantix free 30 day trial 2021All percentages have been calculated using unrounded amounts. Some amounts in this press release may not add due to rounding. Additionally, revenues and expenses associated with the former Upjohn Business (6) and Pfizer’s former Meridian (6) subsidiary, the manufacturer of EpiPen and other auto-injector products, for all periods presented have been recategorized as discontinued operations and excluded from Adjusted (3) results.īusiness development activities completed in 20 (5) impacted financial results in the periods presented (6). Pfizer CentreOne, the company’s contract development and manufacturing organization which previously had been managed within the Hospital therapeutic area, has been moved for all periods presented into a separate operating segment to reflect the company’s revised management structure which went into effect starting in the fourth quarter of 2021. Results for the fourth quarter and full-year 20 (5) are summarized below. I have never been more confident in the future of Pfizer.” Finally, we have prudently deployed our capital through multiple business development transactions in recent months to advance our strategies, always with an eye toward bolstering growth in the latter half of this decade and beyond. In 2021, we exceeded our goal of manufacturing 3 billion doses of Comirnaty (1), a monumental and unprecedented achievement by our Global Supply colleagues. In addition, we just concluded a year where we provided tremendous value to society, including to both patients and shareholders. Today we are issuing guidance for the coming year which, if achieved, would represent the highest level of annual revenues and Adjusted diluted EPS (3) in Pfizer’s long history. As we enter a new year, I look forward to all we will accomplish together.”įrank D’Amelio, Chief Financial Officer, Executive Vice President, stated: “As I prepare to retire as CFO of Pfizer, I am proud to see that the company is performing better than at any other time during my nearly 15 years here. Everywhere I look in the company, I see colleagues who are inspired by what we have achieved to date and filled with determination to be part of the next breakthrough that could change the world for patients in need. Bourla continued: “These successes have not only made a positive difference in the world, but I believe they have fundamentally changed Pfizer and its culture forever. Now, less than two years since we made that commitment, we are proud to say that we have delivered both the first FDA-authorized vaccine against COVID-19 (with our partner, BioNTech) and the first FDA-authorized oral treatment for COVID-19.”ĭr. We put billions of dollars of capital on the line in pursuit of those goals, not knowing whether those investments would ever pay off. Albert Bourla, Chairman and Chief Executive Officer, stated: “In the early days of the COVID-19 pandemic, we committed to use all of the resources and expertise we had at our disposal to help protect populations globally against this deadly virus, as well as to offer treatments to help avoid the worst outcomes when infections do occur. Provides Updates and New Data for Select Clinical Programs Spanning Vaccines, Hospital, Oncology, Rare Disease and Internal Medicine on Analyst Conference Callĭr. Issues Initial 2022 Revenue Guidance for Paxlovid of Approximately $22 Billion, Reflecting Treatment Courses Expected to be Delivered Primarily Under Supply Contracts Signed or Committed as of Late-January Raises 2022 Revenue Guidance for Comirnaty (1) to Approximately $32 Billion, Reflecting Doses Expected to be Delivered Under Supply Contracts Signed as of Late-January Provides Full-Year 2022 Record-High Guidance (4) for Revenues of $98.0 to $102.0 Billion and Adjusted Diluted EPS (3) of $6.35 to $6.55, Reflecting 23% and 46% Year-Over-Year Growth at the Midpoints, Respectively Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billionįourth-Quarter 2021 Revenues of $23.8 Billion, Reflecting 106% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Declined 2% Operationally Driven Primarily by the Impact of Fewer Selling Days Compared to the Prior-Year Quarterįull-Year 2021 Reported Diluted EPS (2) of $3.85, Adjusted Diluted EPS (3) of $4.42 Fourth-Quarter 2021 Reported Diluted EPS (2) of $0.59, Adjusted Diluted EPS (3) of $1.08
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |